Nanobiotix (NASDAQ:NBTX) Reaches New 12-Month High - Should You Buy?

Key Points

• Nanobiotix shares reached a new 52-week high, trading at $21.26, up from a previous close of $20.51, indicating strong market interest.
• Analysts have mixed views on the stock, with a consensus rating of Hold and a target price of $11.00, despite some analysts issuing a Buy rating.
• Institutional investors own 38.81% of Nanobiotix shares, with a recent stake purchase by Millennium Management LLC, suggesting increased institutional confidence in the company.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $21.23 and last traded at $21.26, with a volume of 14391 shares trading hands. The stock had previously closed at $20.51.

Analyst Upgrades and Downgrades

Several analysts have commented on NBTX shares. Leerink Partners set a $14.00 target price on shares of Nanobiotix in a report on Thursday, September 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a research report on Saturday, September 27th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Nanobiotix in a research report on Friday, September 19th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $11.00.

Nanobiotix Stock Performance

The stock has a 50 day moving average price of $10.28 and a two-hundred day moving average price of $6.28.

Institutional Trading of Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Millennium Management LLC bought a new position in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,452 shares of the company's stock, valued at approximately $39,000. 38.81% of the stock is owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.